TribeMD
Eventos
Notícias em alta
ACC 2026Mar 13, 2026
9 min read
2026 AHA ACC Guideline for Acute Pulmonary Embolism
The first-ever AHA/ACC/multi-society dedicated acute PE guideline introduces 5 clinical categories (A-E), redefines anticoagulation strategy, clearly outlines when advanced therapies are indicated, and sets new standards for follow-up. Pulmonary embolism remains the third leading cause of cardiovascular death worldwide and one of the most clinically challenging emergencies physicians
ASCOGU 2026Mar 2, 2026
5 min read
ctDNA after neoadjuvant therapy predicts metastatic risk and may support bladder preservation in MIBC
Integrated analysis of the RETAIN trials highlights the prognostic value of circulating tumor DNA following chemoimmunotherapyThe integration of circulating tumor DNA (ctDNA) into therapeutic decision-making for muscle-invasive bladder cancer (MIBC) was presented as a risk-stratification strategy at the ASCO Genitourinary Cancers Symposium 2026, based on the combined analysis of the phase II RETAIN-1 and RETAIN-2 trials.These studies evaluated a re
ASCOGU 2026Feb 26, 2026
5 min read
Combination of Enzalutamide and Radium-223 Improves Survival in Advanced Prostate Cancer, PEACE-3 Study Shows
Final results of the phase III trial demonstrate a significant overall survival benefit in patients with castration-resistant disease and bone metastasesThe combination of enzalutamide and radium-223 demonstrated a significant overall survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone involvement, according to the final results of the PEACE-3 study presented at the ASCO Genitourinary Cancers Symposium 2026.
OncologyFeb 20, 2026
5 min read
KEYNOTE-905 - EV-303: Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves Event-Free and Overall Survival vs Surgery Alone in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy commonly proceed directly to radical cystectomy with pelvic lymph-node dissection. KEYNOTE-905/EV-303 tested whether adding perioperative systemic therapy could improve outcomes in this population.In this phase 3, open-label trial, adults with clinically nonmetastatic MIBC (T2–T4a N0 M0, or T1–T4a N1 M0) with predominantly urothelial histology (≥50%) who were ineligible for or declin
